摘要
目的探讨塞来昔布对非小细胞肺癌(NSCLC)的化疗增敏作用及其机制。方法应用噻唑蓝比色法(MTT)检测顺铂(DDP)、足叶乙甙(VP16)单独应用及与塞来昔布联合应用的增殖抑制率,并根据金氏公式计算Q值,评价两药的合用效应。应用流式细胞术检测各处理组的凋亡率。结果DDP联合塞来昔布后对NSCLC抑制作用明显增强,二者合用有协同作用。VP16联合塞来昔布后对NSCLC抑制作用明显增强,二者合用有协同作用。塞来昔布与顺铂联合用药的凋亡率明显高于单用药组(P<0.01)。结论塞来昔布可增强DDP、VP16对NSCLC的增殖抑制作用,具有化疗增敏作用,其机制可能与塞来昔布促进凋亡有关。
Objective To investigate the sensitizasion effects and its mechanism of celecoxib in non-smallcell lung cancer （NSCLC）. Methods The inhibitory rate on cell proliferation of NSCLC in celecoxib group, DDP group, VP16 group , DDP with celecoxib group and VP16 with celecoxib group was detected by MTT assay. The Q value was calculated to judge the sensitization effect. The apoptosis of cancer cells were detected by flow cytometry. Results The DDP with celecoxib and VP16 with celecoxib could increase the inhibitory effect on cell proliferation of NSCLC. The synergistic effect of the two drugs was found. The apoptotic rate in DDP with celecoxib group was higher than that in DDP group （ P 〈 0.01 ）. Conclusion The celecoxib could increase the inhibitory effect of DDP and VP16 on cell proliferation of NSCLC and the sensitizasion effect in chemotherapy, which may related with cell apoptosis induced by celecoxib.
出处
《河北医药》
CAS
2006年第9期783-784,共2页
Hebei Medical Journal
